2013 Annual Report
1 / 88Pages

Advancingthe Futureof Healthcare

CONMED Corporation To Our Shareholders: 2013 was a year of strategic focus for CONMED Corporation as we navigated a challenging global operating environment. We achieved a number of key accomplishments in 2013 that reflect our team’s hard work and position the Company for future success. While our top-line growth was short of what we had anticipated at the start of 2013, we adjusted expense levels to deliver earnings within our forecasted range. This is a tribute to the Company’s talented team, which produced results despite a soft worldwide economy. During the year, we launched new...

Adjusted Net Income (in $ millions) Adjusted Net Income CAGR = 14.8% Without the medical device tax in 2013, the Adjusted Net Income CAGR = 16.9% This amount represents adjusted net income excluding the $3.7 million impact of the medical device tax. Reconciliation of Reported Net Income to Non-GAAP Net Income Before Adjusted Items and Amortization of Debt Discount1 (In thousands except per share amounts) (Unaudited) 2009 2010 2011 2012 2013 Reported net income $ 12,137 $ 30,346 $ 752 $ 40,481 $ 35,939 ________ ________ ________ ________ ________ Facility consolidation costs 12,704 2,397...

OurMarkets Revenues by Product Line OrthopedicSurgery54% Sports Medicine Powered Surgical Instruments Sports Biologics & Tissue GeneralSurgery37% Advanced Surgical Energy Endomechanical Instrumentation GI & Pulmonary Patient Monitoring

ProductSpotlight EDGE™ Bipolar Arthroscopic RF System Designed by RF technology innovators, CONMED’s new bi-polar RF Arthroscopic Energy System offers a versatile, intuitive design and user interface for arthroscopic ablation, coagulation and dissection. The system consists of a radio frequency generator, bi-polar probes and optional wired or wireless foot controls. The single-use bi-polar probes are engineered for shoulder, knee, hip and extremity arthroscopy procedures and have the ability to change power settings from the sterile field as well as measure joint fluid temperature....

ProductSpotlightCont. Hall50™ Powered Instruments System Built upon 50 years of dependable power and engineering expertise, the Hall 50 System combines precise performance, reliable power and convenient sterilization into one solution that delivers unmatched value for hospitals, surgeons and OR staff. The lighter, ergonomically-designed handpieces provide a comfortable, high-performance clinical experience while the autoclavable lithium batteries deliver dependable, longlasting power. The unique, multi-tray system also provides hospitals with new levels of sterilization convenience that...

CorporateInformation Board Members Corporate Officers Corporate Office Mark E. Tryniski Chairman of the Board of Directors Curt R. Hartman Interim Chief Executive Officer & Director Brian Concannon Director William W. Abraham Executive Vice President, Business Development CONMED Corporation 525 French Road Utica, NY 13502 Phone (315) 797-8375 Fax (315) 797-0321 Customer Service 1-800-448-6506 email: info@conmed.com website: www.conmed.com Bruce F. Daniels Director Charles M. Farkas Director Jo Ann Golden Director Curt R. Hartman Interim Chief Executive Officer & Director Dirk M. Kuyper...

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2013 Commission file number 0-16093 CONMED CORPORATION (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation or organization) 525 French Road, Utica, New York (Address of principal executive offices) (315) 797-8375 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common...

CONMED CORPORATION ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2013 Item 1A. Risk Factors 9 Item 3. Legal Proceedings 15 Item 4. Mine Safety Disclosures 16 Item 5. Market for Registrant's Common Equity. Related Stockholder Matters and Issuer Purchases of Equity Securities 16 Item 6. Selected Financial Data 19 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 7A. Quantitative and Qualitative Disclosures About Item 8. Financial Statements and Supplementary Data 32 Item 9. Changes In and Disagreements with Accountants on Accounting...

CONMED CORPORATION Item 1. Business Forward Looking Statements This Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2013 (“Form 10-K”) contains certain forwardlooking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to CONMED Corporation (“CONMED”, the “Company”, “we” or “us” — references to “CONMED”, the “Company”, “we” or “us” shall be deemed to include our direct and indirect subsidiaries unless the context otherwise requires) which are based on the beliefs of our management, as well as assumptions...

Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports are accessible free of charge through the Investor Relations section of our website (http://www.conmed.com) as soon as practicable after such materials have been electronically filed with, or furnished to, the United States Securities and Exchange Commission (the "SEC"). Our SEC filings are also available for reading and copying at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room may...

Successful Integration of Acquisitions. We seek to build growth platforms around our core markets through focused acquisitions of complementary businesses and product lines. These acquisitions have enabled us to diversify our product portfolio, expand our sales and marketing capabilities and strengthen our presence in key geographical markets. Strategic Marketing and Distribution Channels. We market our products domestically through five focused sales force groups consisting of approximately 275 employee sales representatives and 215 sales professionals employed by independent sales agent...